

Table 6.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1998 to 2007
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	88	139	134	168	181	160	183	199	173	208
Tx with Antirejection Treatments	20	30	28	20	36	31	34	31	23	37
Antibodies										
Any in Category	55.0%	90.0%	92.9%	65.0%	63.9%	77.4%	55.9%	51.6%	39.1%	54.1%
Atgam/NRATG/NRATS	10.0%	0.0%	0.0%	5.0%	0.0%	0.0%	2.9%	0.0%	0.0%	0.0%
OKT3	50.0%	73.3%	57.1%	30.0%	38.9%	25.8%	20.6%	25.8%	21.7%	16.2%
Thymoglobulin	10.0%	40.0%	57.1%	40.0%	36.1%	54.8%	26.5%	35.5%	13.0%	40.5%
Zenapax	0.0%	13.3%	3.6%	5.0%	2.8%	9.7%	2.9%	0.0%	4.3%	2.7%
Simulect	0.0%	3.3%	3.6%	5.0%	0.0%	0.0%	0.0%	0.0%	4.3%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	11.1%	38.7%	26.5%	3.2%	0.0%	0.0%
Corticosteroids										
Any in Category	70.0%	73.3%	78.6%	90.0%	86.1%	80.6%	85.3%	83.9%	95.7%	94.6%
Steroids	70.0%	73.3%	78.6%	90.0%	86.1%	80.6%	85.3%	83.9%	95.7%	94.6%
Antimetabolites										
Any in Category	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.